{"id":"g-csf-and-plerixafor","safety":{"commonSideEffects":[{"rate":"50-70%","effect":"Bone pain"},{"rate":"30-50%","effect":"Nausea"},{"rate":"20-30%","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL5402188","moleculeType":null,"molecularWeight":"812.50"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"G-CSF stimulates the bone marrow to produce more neutrophils, which are a type of white blood cell. Plerixafor is a CXCR4 antagonist that mobilizes stem cells from the bone marrow into the bloodstream.","oneSentence":"Stimulates the production of neutrophils by binding to the G-CSF receptor","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:33:32.211Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Autologous hematopoietic stem cell mobilization"}]},"trialDetails":[{"nctId":"NCT02015013","phase":"PHASE2","title":"Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-01-15","conditions":"Idiopathic CD4-Positive, T-Lymphocytopenia","enrollment":40},{"nctId":"NCT06325709","phase":"PHASE1, PHASE2","title":"Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-04-17","conditions":"Chronic Granulomatous Disease (CGD), X-Linked Chronic Granulomatous Disease","enrollment":10},{"nctId":"NCT05357482","phase":"PHASE1, PHASE2","title":"Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2022-05-12","conditions":"Sickle Cell Anemia, Beta Thalassemia","enrollment":40},{"nctId":"NCT07423728","phase":"NA","title":"CHRONO-MOBILIZE: Chronotherapy of G-CSF for CD34+ Mobilization in Healthy Donors","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2026-03-01","conditions":"Granulocyte Colony-Stimulating Factor (G-CSF) Mobilization","enrollment":160},{"nctId":"NCT06207799","phase":"PHASE2","title":"Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-07-17","conditions":"Multiple Myeloma, Post-transplant MRD-guided Maintenance Therapy, Pre-transplant Purging","enrollment":40},{"nctId":"NCT06851767","phase":"PHASE1, PHASE2","title":"Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene Therapy","status":"ENROLLING_BY_INVITATION","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-05-09","conditions":"X-linked Severe Combined Immunodeficiency, X-SCID, XSCID","enrollment":18},{"nctId":"NCT06158828","phase":"PHASE1, PHASE2","title":"Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2024-05-15","conditions":"AML, Childhood, Aml, Acute Myeloid Leukemia, Pediatric","enrollment":68},{"nctId":"NCT06414889","phase":"PHASE1","title":"Protocol Title: Safety and Feasibility of Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis in Participants With RUNX1 Familial Platelet Disorder","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-05-20","conditions":"RUNX1 Familial Platelet Disorder","enrollment":4},{"nctId":"NCT05088356","phase":"PHASE1","title":"Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft","status":"RECRUITING","sponsor":"Stanford University","startDate":"2021-09-07","conditions":"Allogeneic Hematopoietic Cell Transplantation (HCT), Advanced Hematologic Malignancies, Acute Leukemia","enrollment":60},{"nctId":"NCT03317899","phase":"PHASE2","title":"Stem Cell Transplant With or Without Tbo-filgrastim in Treating Patients With Multiple Myeloma or Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2017-10-12","conditions":"Non-Hodgkin's Lymphoma, Plasma Cell Myeloma","enrollment":77},{"nctId":"NCT07188090","phase":"PHASE2","title":"Mozobil for Autologous Hematopoietic Stem Cell Transplantation","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2025-10-16","conditions":"Multiple Myeloma, Hodgkin Lymphoma, Non-hodgkin Lymphoma","enrollment":100},{"nctId":"NCT01526096","phase":"PHASE1","title":"Stem Cell Transplantation for Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2011-07-12","conditions":"Myeloma","enrollment":30},{"nctId":"NCT01815749","phase":"PHASE1","title":"Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2013-10-08","conditions":"Adult Grade III Lymphomatoid Granulomatosis, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue","enrollment":30},{"nctId":"NCT05087212","phase":"PHASE4","title":"Mobilization of Stem Cells With AMD3100 (Plerixafor) in Combination With G-CSF in Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2021-10-22","conditions":"Autologous Haematopoietic Stem Cell Transplant","enrollment":53},{"nctId":"NCT07186179","phase":"","title":"Mobilization of CD34+ Peripheral Blood Stem Cells in Patients With Diamond Blackfan Anemia Syndrome (DBAS)","status":"RECRUITING","sponsor":"Northwell Health","startDate":"2025-10-01","conditions":"Diamond Blackfan Anemia","enrollment":10},{"nctId":"NCT03055247","phase":"PHASE2","title":"Combination of Ibuprofen, G-CSF and Plerixafor as Stem Cells Mobilization Regimen in Patients Affected by X-CGD","status":"RECRUITING","sponsor":"IRCCS San Raffaele","startDate":"2015-11-06","conditions":"Chronic Granulomatous Disease X-linked (X-CGD)","enrollment":3},{"nctId":"NCT02678533","phase":"PHASE1, PHASE2","title":"Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and Plerixafor","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-02-10","conditions":"Fanconi Anemia","enrollment":4},{"nctId":"NCT04362293","phase":"PHASE2","title":"Reduced Intensity Transplantation for Severe Sickle Cell Disease","status":"SUSPENDED","sponsor":"St. Jude Children's Research Hospital","startDate":"2020-04-30","conditions":"Sickle Cell Disease","enrollment":40},{"nctId":"NCT01318317","phase":"PHASE1, PHASE2","title":"Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2011-09-19","conditions":"Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma","enrollment":8},{"nctId":"NCT01186224","phase":"NA","title":"Plerixafor Harvesting And No Chemotherapy for Transplantation of Autologous STem Cells In Cancer (PHANTASTIC)","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2010-05","conditions":"Multiple Myeloma, Plasma Cell Dyscrasia, Lymphoma","enrollment":60},{"nctId":"NCT01413100","phase":"PHASE2","title":"Scleroderma Treatment With Autologous Transplant (STAT) Study","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2011-09-15","conditions":"Systemic Scleroderma","enrollment":21},{"nctId":"NCT01331018","phase":"PHASE1","title":"Gene Therapy for Fanconi Anemia","status":"TERMINATED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2012-02-22","conditions":"Fanconi Anemia","enrollment":3},{"nctId":"NCT03157804","phase":"PHASE1, PHASE2","title":"Lentiviral-mediated Gene Therapy of Fanconi Anemia Patients Subtype A","status":"COMPLETED","sponsor":"Hospital Infantil Universitario Niño Jesús, Madrid, Spain","startDate":"2016-01-07","conditions":"Fanconi Anemia","enrollment":9},{"nctId":"NCT04418414","phase":"PHASE1","title":"Hematopoietic Stem Cell Transplantation Gene Therapy for Treatment of Severe Hemophilia A","status":"NOT_YET_RECRUITING","sponsor":"Expression Therapeutics, LLC","startDate":"2024-09-01","conditions":"Hemophilia A","enrollment":7},{"nctId":"NCT03240861","phase":"PHASE1","title":"Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer","status":"TERMINATED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2017-07-26","conditions":"HLA-A*0201 Positive Cells Present, Locally Advanced Malignant Neoplasm, NY-ESO-1 Positive","enrollment":5},{"nctId":"NCT02231879","phase":"PHASE2, PHASE3","title":"Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-10-14","conditions":"Myelokathexis, Infections, Neutropenia","enrollment":20},{"nctId":"NCT05510544","phase":"PHASE4","title":"Plerixafor for Poorly Mobilized Lymphoma","status":"UNKNOWN","sponsor":"Peking University","startDate":"2022-12-19","conditions":"Lymphoma","enrollment":140},{"nctId":"NCT05007652","phase":"PHASE2","title":"A Study of KRN125 in Patients With Multiple Myeloma and Malignant Lymphoma","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2021-09-01","conditions":"Multiple Myeloma and Malignant Lymphoma","enrollment":64},{"nctId":"NCT01746173","phase":"PHASE2","title":"CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2013-07","conditions":"T-cell Non-Hodgkin Lymphoma","enrollment":5},{"nctId":"NCT03612466","phase":"PHASE1","title":"A Dose Finding Study of CycloSam® Combined With External Beam Radiotherapy","status":"WITHDRAWN","sponsor":"Albert Einstein College of Medicine","startDate":"2022-08","conditions":"Osteosarcoma, Bone Metastases","enrollment":""},{"nctId":"NCT00669669","phase":"PHASE1, PHASE2","title":"O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas","status":"TERMINATED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2009-02-25","conditions":"Glioblastoma, Gliosarcoma","enrollment":12},{"nctId":"NCT01123499","phase":"","title":"Collection of Peripheral Blood Stem Cells Using G-CSF and Plerixafor in Normal Volunteers","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-10-06","conditions":"Normal Physiology","enrollment":5},{"nctId":"NCT00082329","phase":"PHASE2","title":"G-CSF and AMD3100 to Mobilize Stem Cells in Healthy Volunteers","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2004-06-18","conditions":"Healthy","enrollment":9},{"nctId":"NCT02703779","phase":"PHASE2","title":"Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM)","status":"COMPLETED","sponsor":"Siddhartha Ganguly","startDate":"2016-03","conditions":"Multiple Myeloma","enrollment":101},{"nctId":"NCT01753453","phase":"PHASE2","title":"An Exploratory Safety Study to Investigate the Extent of Tumor Cell Mobilization (TCM) After Use of G-CSF Alone or G-CSF Plus Plerixafor in Multiple Myeloma (MM) Patients Who May be Poor Mobilizers of Stem Cells","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-06","conditions":"Multiple Myeloma","enrollment":23},{"nctId":"NCT02439476","phase":"","title":"Non-interventional Study on Salvage Auto in Relapsed Myeloma","status":"COMPLETED","sponsor":"Association for Training, Education, and Research in Hematology, Immunology, and Transplantation","startDate":"2016-08-08","conditions":"Relapsed Multiple Myeloma","enrollment":23},{"nctId":"NCT00479115","phase":"PHASE1, PHASE2","title":"Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and AMD3100","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2007-05","conditions":"Fanconi Anemia","enrollment":1},{"nctId":"NCT02750254","phase":"PHASE1","title":"Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2016-06-27","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphocytic Leukemia","enrollment":5},{"nctId":"NCT00822770","phase":"PHASE1, PHASE2","title":"Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-01","conditions":"Stem Cell Transplantation, Leukemia","enrollment":47},{"nctId":"NCT03506802","phase":"PHASE1","title":"TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma","status":"WITHDRAWN","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2018-07-10","conditions":"HLA-A*0201 Positive Cells Present, NY-ESO-1 Positive Tumor Cells Present, Recurrent Plasma Cell Myeloma","enrollment":""},{"nctId":"NCT02931071","phase":"PHASE2","title":"Clinical Phase II Trial to Evaluate CD34+ Cells Mobilization and Collection in Patients With Fanconi Anemia for Subsequent Transduction With a Lentiviral Vector Carring FANCA Gene. FANCOSTEM-1","status":"COMPLETED","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","startDate":"2013-09","conditions":"Fanconi Anemia","enrollment":13},{"nctId":"NCT02416908","phase":"PHASE1, PHASE2","title":"Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2015-06-16","conditions":"Acute Myeloid Leukemia","enrollment":40},{"nctId":"NCT01146834","phase":"PHASE3","title":"Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2011-03","conditions":"Multiple Myeloma","enrollment":47},{"nctId":"NCT02682953","phase":"PHASE2","title":"Hyperbaric Oxygen Therapy for Hematopoietic Progenitor Cell Collection in Poor Mobilizers","status":"WITHDRAWN","sponsor":"University of Maryland, Baltimore","startDate":"2015-10","conditions":"Bone Marrow Transplantation, Hematopoietic Stem Cells, Multiple Myeloma","enrollment":""},{"nctId":"NCT03547830","phase":"PHASE2","title":"Plerixafor/G-CSF as Additional Agents for Conditioning Before HSCT in CGD Patients","status":"UNKNOWN","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2019-04-13","conditions":"Chronic Granulomatous Disease","enrollment":17},{"nctId":"NCT01408043","phase":"NA","title":"Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma","status":"TERMINATED","sponsor":"Case Comprehensive Cancer Center","startDate":"2011-10","conditions":"Adult Acute Lymphoblastic Leukemia in Remission, Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma","enrollment":25},{"nctId":"NCT01818284","phase":"PHASE2","title":"Plerixafor for Stem Cell Mobilization in Normal Donors","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-10","conditions":"Blood And Marrow Transplantation","enrollment":22},{"nctId":"NCT00807599","phase":"PHASE2","title":"Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2008-12-10","conditions":"Multiple Myeloma","enrollment":67},{"nctId":"NCT03019809","phase":"PHASE2","title":"A Trial of Plerixafor/G-CSF as Additional Agents for Conditioning Before TCR Alpha/Beta Depleted HSCT in WAS Patients","status":"UNKNOWN","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2016-06","conditions":"Wiskott-Aldrich Syndrome, Hematopoietic Stem Cell Transplantation, Graft Failure","enrollment":30},{"nctId":"NCT02343666","phase":"PHASE1","title":"HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection","status":"WITHDRAWN","sponsor":"Fred Hutchinson Cancer Center","startDate":"2016-08-15","conditions":"Human Immunodeficiency Virus 1 Positive, Stage I Adult Hodgkin Lymphoma, Stage I Adult Non-Hodgkin Lymphoma","enrollment":""},{"nctId":"NCT01182675","phase":"PHASE2","title":"Hematopoietic Stem Cell Transplantation (HSCT) for Children With SCID Utilizing Alemtuzumab, Plerixafor & Filgrastim","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2010-08","conditions":"Severe Combined Immunodeficiency","enrollment":7},{"nctId":"NCT01547806","phase":"PHASE2","title":"Collection of Transplant Stem Cells for Plasma Cell Myeloma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2012-02-22","conditions":"Plasma Cell Myeloma, Multiple Myeloma","enrollment":49},{"nctId":"NCT00075335","phase":"PHASE2","title":"AMD 3100 (Mozobil Plerixafor) to Mobilize Stem Cells for Donation","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2004-01","conditions":"Healthy","enrollment":8},{"nctId":"NCT01097057","phase":"PHASE2","title":"Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2010-11-09","conditions":"Non-Hodgkin Lymphoma","enrollment":20},{"nctId":"NCT03244930","phase":"PHASE2","title":"Low Dose Plerixafor Plus G-CSF in Mobilizing Stem Cells for Autologous Peripheral Blood Transplantation","status":"UNKNOWN","sponsor":"Hospital Universitario Dr. Jose E. Gonzalez","startDate":"2017-05-10","conditions":"Lymphoma, Non-Hodgkin, Lymphoma, Hodgkin, Myeloma","enrollment":20},{"nctId":"NCT01403896","phase":"PHASE2","title":"Healthy Donor Study II - Comparing Plerixafor With G-CSF and Plerixafor","status":"COMPLETED","sponsor":"Stephen Couban","startDate":"2012-04","conditions":"Malignant Lymphoma, Stem Cell Type","enrollment":10},{"nctId":"NCT01339572","phase":"PHASE2","title":"Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation","status":"COMPLETED","sponsor":"University of Florida","startDate":"2011-04","conditions":"Non-Hodgkin's Lymphoma, Multiple Myeloma","enrollment":72},{"nctId":"NCT02098109","phase":"PHASE2","title":"Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2014-08-20","conditions":"Multiple Myeloma, Lymphoma, Non-Hodgkin","enrollment":100},{"nctId":"NCT01076270","phase":"NA","title":"Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies","status":"TERMINATED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2010-06","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission","enrollment":1},{"nctId":"NCT01158118","phase":"PHASE2","title":"Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2011-04-01","conditions":"Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Lymphoma, Non-Hodgkin","enrollment":48},{"nctId":"NCT01435343","phase":"PHASE1, PHASE2","title":"Treatment of Relapsed or Refractory Acute Myeloblastic Leukemia","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2012-07","conditions":"Acute Myeloblastic Leukemia","enrollment":55},{"nctId":"NCT00906945","phase":"PHASE1, PHASE2","title":"Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2011-02","conditions":"Leukemia, Myeloid, Acute","enrollment":39},{"nctId":"NCT00943943","phase":"PHASE1","title":"Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2010-10-29","conditions":"Acute Myelogenous Leukemia, Leukemia","enrollment":33},{"nctId":"NCT01065129","phase":"PHASE1","title":"Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) in Combination With Azacitidine for the Treatment of Myelodysplastic Syndrome (MDS)","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2010-09-02","conditions":"Myelodysplastic Syndromes","enrollment":28},{"nctId":"NCT00733824","phase":"PHASE1, PHASE2","title":"Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With Lymphoma","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2008-11","conditions":"Lymphoma, Non-Hodgkin, Hodgkin Disease","enrollment":61},{"nctId":"NCT01026987","phase":"PHASE1","title":"Granulocyte Colony-stimulating Factor (G-CSF) Plus or Minus AMD3100 for Engraftment Post Allogeneic Transplant","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2010-04-29","conditions":"Stem Cell Transplant Patients","enrollment":29},{"nctId":"NCT02997813","phase":"","title":"Assessment of Mobilization Cost for Multiple Myeloma Using 2 Different Mobilization Strategies","status":"COMPLETED","sponsor":"Intergroupe Francophone du Myelome","startDate":"2015-06","conditions":"Multiple Myeloma, Blood Stem Cell Transplant Failure","enrollment":112},{"nctId":"NCT01362972","phase":"","title":"Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry on a Cohort of Patients Receiving Plerixafor","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2011-03","conditions":"Lymphoma, Multiple Myeloma","enrollment":7801},{"nctId":"NCT02221492","phase":"PHASE2","title":"Plerixafor Plus Granulocyte Colony-Stimulating Factor For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2014-11","conditions":"Lymphoma","enrollment":32},{"nctId":"NCT01455025","phase":"PHASE1","title":"Study in Plerixafor and Granulocyte-colony Stimulating Factor Patients With Relapse Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"French Innovative Leukemia Organisation","startDate":"2012-01","conditions":"Acute Myeloid Leukemia","enrollment":11},{"nctId":"NCT01164345","phase":"PHASE2","title":"Mozobil for Autologous Stem Cell Mobilization","status":"COMPLETED","sponsor":"Sheba Medical Center","startDate":"2010-06","conditions":"Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Stem Cell Mobilization","enrollment":20},{"nctId":"NCT02221479","phase":"PHASE2","title":"Plerixafor Plus Granulocyte Colony-stimulating Factor (G-CSF) For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Multiple Myeloma","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2014-10","conditions":"Multiple Myeloma","enrollment":14},{"nctId":"NCT00998049","phase":"PHASE2","title":"Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2009-12","conditions":"Multiple Myeloma, Refractory Multiple Myeloma, Stage I Multiple Myeloma","enrollment":40},{"nctId":"NCT00395967","phase":"PHASE2","title":"AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients Predicted to be Unable to Mobilize With G-CSF Alone","status":"TERMINATED","sponsor":"Genzyme, a Sanofi Company","startDate":"2005-04","conditions":"Multiple Myeloma, Lymphoma, Non-Hodgkin's","enrollment":5},{"nctId":"NCT00838357","phase":"PHASE3","title":"A Multi-centre, Open Label, Single-arm Study Intended to Further Investigate the Safety and Efficacy of Plerixafor as a Front-line Mobilisation Agent in Combination With G-CSF in Patients With Lymphoma or MM (Multiple Myeloma).","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2008-09","conditions":"Lymphoma (Non-Hodgkin's Lymphoma), Hodgkin's Disease or Multiple Myeloma, Front Line Mobilization","enrollment":118},{"nctId":"NCT00720603","phase":"","title":"This is a Multi-center, Single Arm, Open Label Study Intended to Provide Expanded Access to Plerixafor for Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) Who Are to Receive Treatment With an Autologous Peripheral Stem Cell Transplant.","status":"NO_LONGER_AVAILABLE","sponsor":"Genzyme, a Sanofi Company","startDate":"","conditions":"Non-Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma","enrollment":""},{"nctId":"NCT00741780","phase":"","title":"Long-Term Follow-up Study for Multiple Myeloma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3102 Study (NCT00103662).","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2006-06","conditions":"Multiple Myeloma, Autologous Transplantation","enrollment":164},{"nctId":"NCT01206075","phase":"NA","title":"Evaluating the Safety and Effectiveness of Mozobil Mobilization in Adults With Beta-Thalassemia Major","status":"COMPLETED","sponsor":"University of Washington","startDate":"2010-10","conditions":"Beta-Thalassemia","enrollment":20},{"nctId":"NCT01767714","phase":"PHASE3","title":"Evaluation of Plerixafor Plus G-CSF to Mobilize and Collect 5×10^6CD34+ Cells/kg in Non-Hodgkin's Lymphoma (NHL) Patients for Autologous Transplantation","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-04","conditions":"Non-Hodgkin's Lymphoma","enrollment":100},{"nctId":"NCT01095757","phase":"PHASE2","title":"Evaluation of the Drug Plerixafor in Combination With Chemotherapy and G-CSF for Stem Cell Collection","status":"COMPLETED","sponsor":"Emory University","startDate":"2010-03","conditions":"Myeloma, Lymphoma","enrollment":45},{"nctId":"NCT01301963","phase":"PHASE3","title":"Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide","status":"TERMINATED","sponsor":"Case Comprehensive Cancer Center","startDate":"2011-07","conditions":"Refractory Multiple Myeloma","enrollment":9},{"nctId":"NCT01225419","phase":"PHASE2","title":"Mobilization by Plerixafor of Haematopoietic Stem Cells in Children","status":"COMPLETED","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2010-09","conditions":"Children Cancer, Solid Tumor","enrollment":5},{"nctId":"NCT00901225","phase":"PHASE2","title":"Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant","status":"COMPLETED","sponsor":"Duke University","startDate":"2009-05","conditions":"Multiple Myeloma, Non-Hodgkins Lymphoma, Hodgkins Disease","enrollment":21},{"nctId":"NCT01220375","phase":"PHASE2","title":"PAV-trial: Plerixafor and Chemotherapy With Vinorelbine for Stem Cell Mobilization in Patients With Myeloma","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2010-04","conditions":"Myeloma","enrollment":44},{"nctId":"NCT00103662","phase":"PHASE3","title":"Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2005-01","conditions":"Multiple Myeloma","enrollment":302},{"nctId":"NCT00103610","phase":"PHASE3","title":"Mobilization of Stem Cells With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma Patients","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2005-01","conditions":"Lymphoma, Non-Hodgkin","enrollment":298},{"nctId":"NCT00322491","phase":"PHASE2","title":"Mobilization of Stem Cells With AMD3100 (Plerixafor) and G-CSF in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2004-03","conditions":"Lymphoma, Non-Hodgkin, Multiple Myeloma","enrollment":49},{"nctId":"NCT00322842","phase":"PHASE2","title":"Treatment With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2004-09","conditions":"Lymphoma, Non-Hodgkin, Multiple Myeloma","enrollment":35},{"nctId":"NCT00444912","phase":"PHASE2","title":"The Effect of Rituximab on Mobilization With AMD3100 (Plerixafor) Plus G-CSF in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD)","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2006-02","conditions":"Non-Hodgkin Lymphoma, Hodgkin Disease","enrollment":30},{"nctId":"NCT00396331","phase":"PHASE2","title":"AMD3100 (Plerixafor) With G-CSF in Poor Mobilizing Adult Patients Who Previously Failed Hematopoietic Stem Cell (HSC) Collection/Attempts","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2005-10","conditions":"Autologous Stem Cell Transplantation","enrollment":100},{"nctId":"NCT00396201","phase":"PHASE2","title":"AMD3100 (Plerixafor) Added to a Mobilizing Regimen of Granulocyte-colony Stimulating Factor (G-CSF) to Increase the Number of Peripheral Blood Stem Cells (PBSCs) in Patients With Hodgkin's Disease","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2004-11","conditions":"Hodgkin's Disease","enrollment":22},{"nctId":"NCT00322387","phase":"PHASE2","title":"Mobilization of Stem Cells With Plerixafor, Chemotherapy and G-CSF in Multiple Myeloma or Non-Hodgkin's Lymphoma Patients","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2004-04","conditions":"Lymphoma, Non-Hodgkin, Multiple Myeloma","enrollment":40},{"nctId":"NCT00396266","phase":"PHASE2","title":"AMD3100 (Plerixafor) Given to NHL and MM Patients to Increase the Number of PBSCs When Given a Mobilizing Regimen of G-CSF","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2005-01","conditions":"Multiple Myeloma, Lymphoma, Non-Hodgkin","enrollment":22},{"nctId":"NCT01164475","phase":"PHASE4","title":"Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2010-10","conditions":"Non-Hodgkin's Lymphoma","enrollment":61},{"nctId":"NCT00291811","phase":"","title":"Access Program for Use of AMD3100 to Increase Peripheral Blood Stem Cells for Transplantation in Patients Who Have Failed Standard Therapy Stem Cell Mobilization","status":"APPROVED_FOR_MARKETING","sponsor":"Genzyme, a Sanofi Company","startDate":"2003-10","conditions":"Autologous Stem Cell Transplant","enrollment":""},{"nctId":"NCT00665314","phase":"PHASE2","title":"Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM).","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2007-11","conditions":"Lymphoma, Non Hodgkin's Lymphoma, Hodgkin's Disease","enrollment":5},{"nctId":"NCT00741325","phase":"","title":"Long-Term Follow-up Study for Non-Hodgkin's Lymphoma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3101 Study (NCT00103610).","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2006-06","conditions":"Non-Hodgkin's Lymphoma, Autologous Transplantation","enrollment":178},{"nctId":"NCT01149863","phase":"PHASE2","title":"Alteration in Timing of Plerixafor Administration","status":"COMPLETED","sponsor":"Emory University","startDate":"2010-06","conditions":"Autologous Transplantation","enrollment":34},{"nctId":"NCT01074060","phase":"PHASE1","title":"Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2010-04","conditions":"Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma","enrollment":18},{"nctId":"NCT01711073","phase":"PHASE1","title":"Mobilization of Stem Cells With G-CSF and Mozobil in Patients With End Stage Liver Disease","status":"UNKNOWN","sponsor":"Proteonomix, Inc.","startDate":"2012-10","conditions":"End Stage Liver DIsease","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Mozobil","AMD3100"],"phase":"phase_2","status":"active","brandName":"G-CSF and plerixafor","genericName":"G-CSF and plerixafor","companyName":"Genzyme, a Sanofi Company","companyId":"genzyme-a-sanofi-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Stimulates the production of neutrophils by binding to the G-CSF receptor Used for Autologous hematopoietic stem cell mobilization.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}